This company has been acquired
Resumen de acción PRTK
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Paratek Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.23 |
| 52 Week High | US$3.65 |
| 52 Week Low | US$1.29 |
| Beta | 1.7 |
| 1 Month Change | 2.29% |
| 3 Month Change | 0.91% |
| 1 Year Change | -2.62% |
| 3 Year Change | -60.95% |
| 5 Year Change | -77.01% |
| Change since IPO | -86.06% |
Noticias y actualizaciones recientes
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17
Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Rentabilidad de los accionistas
| PRTK | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 2.3% | 0.3% | 3.3% |
| 1Y | -2.6% | 12.0% | 25.0% |
Rentabilidad vs. Industria: PRTK underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.
Rentabilidad vs. Mercado: PRTK underperformed the US Market which returned 13.8% over the past year.
Volatilidad de los precios
| PRTK volatility | |
|---|---|
| PRTK Average Weekly Movement | 1.6% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: PRTK has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: PRTK's weekly volatility has decreased from 13% to 2% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1996 | 269 | Evan Loh | www.paratekpharma.com |
Resumen de fundamentos de Paratek Pharmaceuticals, Inc.
| Estadísticas fundamentales de PRTK | |
|---|---|
| Capitalización bursátil | US$127.83m |
| Beneficios(TTM) | -US$62.73m |
| Ingresos (TTM) | US$177.00m |
0.7x
Ratio precio-ventas (PS)-2.0x
Ratio precio-beneficio (PE)¿Está PRTK sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PRTK | |
|---|---|
| Ingresos | US$177.00m |
| Coste de los ingresos | US$64.13m |
| Beneficio bruto | US$112.87m |
| Otros gastos | US$175.60m |
| Beneficios | -US$62.73m |
Últimos beneficios comunicados
Jun 30, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.09 |
| Margen bruto | 63.77% |
| Margen de beneficio neto | -35.44% |
| Ratio deuda/patrimonio | -128.3% |
¿Cómo se ha desempeñado PRTK a largo plazo?
Ver rendimiento histórico y comparativa